激素性青光眼的研究进展

目的自激素性青光眼首次报道以来已有50多年,人们对于激素性青光眼的危险因素、发病机制和防治都有了进一步的了解。原发性开角型青光眼患者及其亲属,高度近视眼患者等对激素治疗引起的眼压增高较敏感。糖皮质激素主要是通过糖皮质激素受体发挥作用,使小梁网的细胞外基质沉积,增加房水流出阻力而导致眼压升高。进一步了解激素性青光眼的危险因素和发病机制可以有助于我们更好的预防和治疗激素性青光眼。     

Corticosteroid-induced ocular hypertension. II. An acquired form.

Thirty-five patients with unilateral closed-angle glaucoma treated by peripheral iridectomy and prophylactic peripheral iridectomy in the fellow eyes were subjected to corticosteroid provocative test in both eyes. 51% of the eyes with closed-angle glaucoma and 11% of their fellow eyes had a positive corticosteroid pressure response. The closed-angle glaucoma eyes had their fellow eyes responded differently as shown by the frequency distribution graphs and also by the difference between the corticosteroid-induced change in pressure (Wilcoxon test, z=-4.80, p less than 0.0001). These results provide evidence for an acquired form of corticosteroid-induced ocular hypertension and the possible pathogenic factors for the first time. The clinical significance of an acquired form of corticosteroid-induced ocular hypertension is discussed.     

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review

The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect patients who are at risk of glaucomatous optic neuropathy. As expected, volume-driven, acute ocular hypertension immediately follows intravitreal injection, but this pressure elevation is generally transient and well tolerated. Several medications have been investigated to limit acute ocular hypertension following anti-VEGF therapy, but the benefits of pretreatment are not conclusive. Chronic, sustained ocular hypertension, distinct from the short-term acute ocular hypertension after each injection, has also been associated with repeated intravitreal anti-VEGF injections. Risk factors for chronic ocular hypertension include the total number of injections, a greater frequency of injection, and preexisting glaucoma. Proposed mechanisms for chronic ocular hypertension include microparticle obstruction, toxic or inflammatory effects on trabecular meshwork, as well as alterations in outflow facility by anti-VEGF agents. Although limiting anti-VEGF therapy could minimize the risk of both acute and chronic ocular hypertension, foregoing anti-VEGF therapy risks progression of various macular diseases with resulting permanent central vision loss. While definitive evidence of damage to the retinal nerve fiber layer is lacking, patients receiving repeated injections should be monitored for ocular hypertension and patients in whom sustained ocular hypertension subsequently developed should be periodically monitored for glaucomatous changes with optic nerve optical coherence tomography and static visual fields.     

Corticosteroid-induced ocular hypertension. I. Prevalence in closed-angle glaucoma.

Forty-eight eyes with closed-angle glaucoma and 31 eyes at risk were subjected to corticosteroid provocative tests. 65% and 9.7% respectively responded with a change in pressure greater than or equal to 6 mmHg. The responses of the 2 groups were compared with each other and also with the corticosteroid pressure response in normal eyes. The differences in behaviour between the eyes with closed-angle glaucoma and eyes at risk, and the eyes with closed-angle glaucoma and normal eyes, are statistically highly significant. The implication of this are discussed. The prevalence of corticosteroid-induced ocular hypertension in closed-angle glaucoma is higher than previously reported.     

Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide

PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma. DESIGN: Observational case report. METHODS: Retrospective review of a clinical case. RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema. CONCLUSIONS: Intravitreal injection of triamcinolone is a commonly performed treatment for many retinal conditions. This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.     

准分子激光角膜屈光术后皮质类固醇性高眼压临床相关因素分析

目的:探讨准分子激光角膜屈光术后皮质类固醇性高眼压的发生率、临床相关凶素及预后.方法:对2005-12/2006-12间行LASIK或LASEK的2060例4060眼滴糖皮质激素眼液(1g/L地塞米松及1g/L氟米龙)2～3mo,术后1wk;1,2,3,6mo及1α观察眼压变化,对高眼压者进行治疗,并采用Logistic方法分析高眼压与年龄、性别、眼别、最大径线屈光度、最大径线角膜曲率、角膜切削深度和眼底垂直径杯/盘比值的相关性.结果:有88例143眼发生了高眼压,发生率为3.5%,所有高眼压患者经药物治疗眼压均降至正常.Logistic回归分析结果显示,眼底杯/盘比值与高眼压相关性P值为0.015,OR值为3.071,其他因素P值均大于0.1.眼底垂直径杯/盘比值大于等于0.4者发生皮质类固醇性高眼压的几率是小于0.4者的3.071倍.结论:准分子激光角膜屈光术后应用糖皮质激素眼液可引起部分患者发生皮质类固醇性高眼压,眼底垂直径杯/盘比值与皮质类固醇性高眼压有较强相关性,大于等于0.4是皮质类固醇性高眼压的高危因素,对眼底杯/盘比值大于等于0-4者术后可酌情减少激素用量和/或加用降眼压药物.     

白内障术后激素性高眼压危险因素的临床分析

目的:研究白内障术后激素性高眼压发生的危险因素,期望对临床白内障术后糖皮质激素的使用具有一定的指导作用。方法:回顾性分析2005-01/2006-12行白内障超声乳化联合人工晶状体植入术患者糖皮质激素使用后眼压情况。结果:使用糖皮质激素眼液的患者1459例中24例发生糖皮质激素性高眼压,男14例,女10例,年龄、高度近视、糖尿病、术前眼外伤、术前色素膜炎为白内障摘除联合人工晶状体植入术后糖皮质激素性高眼压的危险因素。结论:白内障摘除联合人工晶状体植入术后糖皮质激素性高眼压的发生率为1.36%。眼局部长期大量使用激素是其发生的重要危险因素。     

Evolving global risk assessment of ocular hypertension to glaucoma

PURPOSE OF REVIEW: To discuss current knowledge of global risk assessment in ocular hypertension. RECENT FINDINGS: The ophthalmologist treating patients with ocular hypertension is frequently faced with the clinical dilemma of which patients to treat and how vigorous treatment should be. The goal of risk assessment for glaucoma is to identify patients at greatest risk for symptomatic vision loss. Risk factors can be identified by history such as age, race, and family history or can be clinically observed by examination such as elevated intraocular pressure, optic nerve head appearance, central corneal thickness, and visual field abnormalities. Risk assessment is a well accepted tool in other fields of medicine. Parallels can be drawn between the evolution of risk assessment for coronary artery disease and glaucoma. Validated risk calculators for ocular hypertension are currently available mostly derived from the Ocular Hypertension Treatment Study. SUMMARY: The aim of assessing global risk for conversion from ocular hypertension to glaucoma is to identify patients who are most likely to benefit from early treatment. Calculation of risk should be accompanied by thorough analysis of risks, benefits, and alternatives for the individual patient.     

原发性开角型青光眼进展的危险因素研究概况

原发性开角型青光眼(POAG)进展的危险因素包括全身性及眼部因素,眼部因素包括眼压及非眼压因素.在以往的多中心研究中,眼压对于由高眼压症发展为POAG及其在POAG进展中的作用已经明确,而目前降低眼压也是临床惟一有效地延缓、控制青光眼视神经损害进展的主要因素.制定目标眼压,进行降眼压治疗尤其是控制昼夜眼压波动对于阻止青光眼进展非常重要.非眼压危险因素包括高龄、中央角膜厚度增厚、视乳头出血、晶状体囊膜剥脱征、初始的青光眼严重程度及双眼罹患青光眼等.其他因素包括近视、青光眼家族史、眼部低灌注压、低血压、心血管疾病、高血压、高血脂等血管或血液性因素.POAG进展的危险因素研究在一定程度上揭示了POAG的发病机制及临床发病规律,对于指导临床医师决定随诊频率、选择治疗方案及提高治疗效率意义重大.     

Persisent ocular hypertension following intravitreal ranibizumab

BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally. METHODS: Case series. RESULTS: Four patients had high intraocular pressure after intravitreal ranibizumab 0.5 mg. Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2. In patient 4, it occurred several hours after the first ranibizumab injection. In all patients, the IOP increase was sustained across several visits, requiring control with topical glaucoma therapy, and in two cases the addition of a systemic carbonic anhydrase inhibitor. None of the patients had a previous history of glaucoma, ocular hypertension or IOP asymmetry and the IOP was as high as 30, 34, 46, and 50 mmHg in the four patients. CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab. Although the mechanism of the pressure rise is unknown, all eyes in our series were controlled with medical therapy.     

Risk assessment in the management of patients with ocular hypertension

PURPOSE: To develop a model for estimating the global risk of disease progression in patients with ocular hypertension and to calculate the "number-needed-to-treat" (NNT) to prevent progression to blindness as an aid to practitioners in clinical decision making. DESIGN: Development of a mathematical model for estimating risk of glaucoma progression. METHODS: Population-based studies of patients with ocular hypertension and glaucoma were reviewed by a panel of glaucoma specialists. Measures of disease progression risks derived from three long-term studies and assumptions based on the available data were used to estimate the risk of progression from ocular hypertension to glaucoma and glaucoma to unilateral blindness for untreated and treated patients over a 15-year period. Using these estimates, the NNT (1/absolute risk reduction on treatment) to prevent unilateral blindness in one patient with ocular hypertension was calculated. RESULTS: In untreated patients, the estimated risk of progression from ocular hypertension to unilateral blindness was 1.5% to 10.5% and in treated patients, the estimated risk of progression was 0.3% to 2.4% over 15 years. From these estimates, between 12 and 83 patients with ocular hypertension will require treatment to prevent one patient from progressing to unilateral blindness over a 15-year period. CONCLUSION: Global risk assessment that incorporates all available data plays a vital role in managing patients with ocular hypertension. A more precise understanding of long-term vision loss should be factored into decisions pertaining to the initiation of glaucoma therapy. Undoubtedly, these estimates will evolve and change with the availability of new population-based epidemiologic information and improvements in multivariable model testing.     

Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study

OBJECTIVE: To assess the impact of vascular risk factors on the prevalence of primary open angle glaucoma. DESIGN: Population-based cross-sectional study. PARTICIPANTS: Four thousand two hundred ninety-seven patients more than 40 years of age underwent a complete ocular examination in the context of the Egna-Neumarkt Glaucoma Study. INTERVENTION: Ocular examinations were performed by trained, quality-controlled ophthalmologists according to a predefined standardized protocol including medical interview, blood pressure reading, applanation tonometry, computerized perimetry, and optic nerve head examination. MAIN OUTCOME MEASURES: Prevalences of ocular hypertension, primary open-angle glaucoma, normal-tension glaucoma, and other types of glaucoma were determined. Correlation coefficients were calculated for the association between systemic blood pressure and age-adjusted intraocular pressure (IOP) and between age and both intraocular and systemic blood pressures. Odds ratios were computed to assess the risk of primary open-angle glaucoma and normal-tension glaucoma in relation to systemic hypertension or antihypertensive medication, blood pressure levels, diastolic perfusion pressure, and a number of other cardiovascular risk factors. RESULTS: A positive correlation was found between systemic blood pressure and IOP, and an association was found between diagnosis of primary open-angle glaucoma and systemic hypertension. Lower diastolic perfusion pressure is associated with a marked, progressive increase in the frequency of hypertensive glaucoma. No relationship was found between systemic diseases of vascular origin and glaucoma. CONCLUSIONS: Our data are in line with those reported in other recent epidemiologic studies and show that reduced diastolic perfusion pressure is an important risk factor for primary open-angle glaucoma.     

Vascular risk factors in glaucoma: a review

Glaucoma, one of the major causes of blindness in the world, is a progressive optic neuropathy. Elevated intraocular pressure is a well-known major risk factor for glaucoma. In addition, there is growing evidence that vascular factors may play a role in glaucoma pathogenesis. Systemic (e.g. hypertension, diabetes) and ocular vascular factors (e.g. ocular blood flow, ocular perfusion pressure) have been assessed for associations with glaucoma. However, direct and convincing evidence for primary mechanisms of glaucoma is still lacking. The aim of this review is to summarize the evidence implicating vascular factors in the pathogenesis of glaucoma, with particular emphasis on the role of ocular blood flow and ocular circulation as risk factors for primary open angle glaucoma.     

Glaucoma clinical trials and what they mean for our patients

PURPOSE: To provide a perspective on the several randomized clinical trials in glaucoma, to suggest how their results can be used in clinical practice, and to look to the future of glaucoma therapy. DESIGN: A search and review of the glaucoma clinical trials literature, the glaucoma observational studies literature, and the evidence-based medicine literature. METHODS: Analysis of the significance of glaucoma clinical trials data on patient management along with use of patient data to demonstrate how treatment decisions can be used in the practice setting. RESULTS: Glaucoma clinical trials and observational studies strongly support the need to reduce intraocular pressures (IOP) substantially and to maintain those pressures in patients with advanced glaucoma. Whether this aggressive therapy occurs by medications or by filtering surgery does not seem as important as that the treatment is effective and sustained. However, there is not the same strength of evidence for aggressive treatment or even any treatment for most patients with ocular hypertension and for some cases of early glaucoma. Because about half of the patients with open-angle glaucoma will have IOPs less than 21 mm Hg, these patients need to be detected through careful optic disk and visual field assessment. Once patients are detected and treated appropriately, blindness from open-angle glaucoma is unlikely. CONCLUSIONS: The goal of managing ocular hypertension and glaucoma is not to preserve every ganglion cell, but rather to preserve a patient's visual ability to conduct activities of daily living. Risk factors for damage need to be assessed for individual patients and each patient managed as an individual and not as the "average" patient depicted in the results of clinical trials. In the future, neuroprotective therapy other than IOP reduction will provide another means to control glaucoma damage.     

Comparative results of central corneal thickness measurements in primary open-angle glaucoma, pseudoexfoliation glaucoma, and ocular hypertension.

BACKGROUND AND OBJECTIVE: As clinical measurements of corneal thickness have become widely available, several studies found a positive correlation between central corneal thickness and applanation tonometry measurements. This study evaluated central corneal thickness in different types of glaucoma. PATIENTS AND METHODS: An observational cross-sectional study assessed central corneal thickness using a specular microscope in the following groups of patients: 60 eyes with primary open-angle glaucoma, 50 eyes with pseudoexfoliation glaucoma, 50 eyes with ocular hypertension, and 60 eyes without glaucoma or ocular hypertension (control group). RESULTS: Central corneal thickness was significantly thinner in cases with pseudoexfoliation glaucoma (P < .0001) and significantly thicker in cases with ocular hypertension (P< .0001). CONCLUSIONS: These results agree with the literature, strengthening the position that central corneal thickness varies in different types of glaucoma and, therefore, is a parameter that should be taken under consideration, especially when evaluating cases of pseudoexfoliative glaucoma and ocular hypertension.     

The relationship between intraocular pressure and glaucoma in a defined population. Data from the Egna-Neumarkt Glaucoma Study

PURPOSE: To provide data on the prevalence of ocular hypertension and glaucoma and on the diagnostic validity of tonometry. METHODS: In this cross-sectional, population-based study, 4,927 subjects over 40 years of age were examined. Each subject underwent a complete ocular examination as part of the Egna-Neumarkt Glaucoma Study. These examinations were carried out by trained, quality-controlled ophthalmologists, according to a predetermined standard protocol that included a medical interview, applanation tonometry, computerized perimetry, optic nerve head examination and other ocular measurements. The following data were recorded: mean IOP, prevalence of ocular hypertension, primary open-angle glaucoma and normal tension glaucoma. Sensitivity, specificity and the predictive value of the tonometric test, as well as the distribution of IOP in the different groups were also determined. RESULTS: The overall prevalence of ocular hypertension, hypertensive primary open-angle glaucoma and normal tension glaucoma corresponded to 2.1, 1.4 and 0.6%, respectively. Other types of glaucoma accounted for a further 0.9%. The sensitivity and specificity of the tonometric test in recognizing glaucoma (cut-off between 21 and 22 mm Hg) were, respectively, 80.1 and 97.8%. The predictive values of the positivity and negativity of the test were 52.1 and 99.4%, respectively. CONCLUSIONS: The prevalence of ocular hypertension and glaucoma was similar to that found in several recent epidemiological studies. Tonometry alone is obviously not sufficient to ascertain or to exclude the presence of glaucoma; its diagnostic validity however is high and should never be underestimated. An elevated IOP is the main risk factor for glaucoma, with the degree of risk increasing as the level of IOP increases.     

Retinal vascular events after intravitreal bevacizumab

Acta Ophthalmol. 2010: 88: 730–735

Abstract.

Purpose: To record retinal vascular events following intravitreal bevacizumab injection. Methods: Collaborative multi‐centre retrospective case series. Results: Eight patients were documented to have central retinal artery occlusion (four patients), branch retinal artery occlusion, capillary occlusion, central retinal vein occlusion and branch retinal vein occlusion (one patient each) within 0–55 days (median 2 weeks) of intravitreal bevacizumab. All patients had several ocular and systemic risk factors for retinal vascular events: elevated intraocular pressure on discharge (four patients), pre‐existent glaucoma (one patient), pre‐existent ischaemic retinal vascular disorder (four patients), systemic hypertension (five patients), diabetes mellitus (three patients), coronary artery disease (four patients), carotid disease (three patients), smoking (two patients) and migraine (one patient). Conclusion: The retinal vascular events may be associated with the underlying ocular disease under treatment or with the underlying systemic disease, may be related to an increased intraocular pressure post‐injection constraining further an already poor retinal perfusion, the vasoconstrictor effect of bevacizumab, or a combination of all three.     

Abgrenzung der okulären Hypertension

The term ocular hypertension has been used for more than 30 years. It is defined as an elevated intraocular pressure above the statistical norm without detectable optic nerve head or visual field damage. The number of patients with ocular hypertension in Germany is estimated to be approximately 3–5 million. Increased intraocular pressure is a risk factor for conversion to primary open-angle glaucoma. Most patients with ocular hypertension (and no risk factors) can be followed on a regular basis without any treatment. Each visit should include measurement of intraocular pressure, optic nerve head examination with a slit lamp, imaging and perimetric examinations. Currently known risk factors are high intraocular pressure, higher age, myopia, a thin cornea and darkly pigmented skin. If risk factors are present, antiglaucomatous therapy is indicated.     

The Natural Course Of Ocular Hypertension and Its Significance In Glaucoma

ABSTRACT The prevalence of ocular hypertension and its role in the aetiology of glaucoma is examined. A follow up study of ocular hypertensive patients of an optometrist suggests that neither the level of I.O.P. between 21 mm Hg and 29 mm Hg, the duration of hypertension nor the age of the patient have value in predicting the natural course of the condition. Since raised I.O.P. is not necessarily present in subjects having typical glaucomatous field loss, a finding of pressures within the normal range should not influence the decision making process for management of patients having risk factors or other signs of glaucoma. Guidelines are suggested for the management of those ocular hypertensive patients for whom careful assessment indicates a low risk of glaucoma.     

Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data

BACKGROUND: Effective management of ocular hypertension requires patients to be persistent with their treatment regimen. We evaluated patients' persistency with hypotensive eyedrops commonly used to treat glaucoma and ocular hypertension. METHODS: This large, population-based, retrospective, cohort study used pharmacy claims data for concessional patients from the Australian Pharmaceutical Benefits Scheme (July 1999-June 2005). Resupply rates for prostaglandins, beta-blockers, alpha-agonists and carbonic anhydrase inhibitors were analysed using life tables and Cox regression. Two populations, based on patients' supply histories, were examined: (i) 'new to this eyedrop'- patients who had used other hypotensive eyedrops before (presumably, previously diagnosed with glaucoma or ocular hypertension); and (ii) 'new to any eyedrop'- patients who were using their first hypotensive eyedrop (presumably, newly diagnosed with glaucoma or ocular hypertension). RESULTS: Data were obtained for 14,359,618 supplies of commonly used hypotensive eyedrops to 357,099 concessional patients. For both populations, resupply rates were highest for prostaglandins or the dorzolamide-timolol combination eyedrops, compared with beta-blockers, alpha-agonists or carbonic anhydrase inhibitors. Among the prostaglandins, there was no significant difference in the risk of ceasing supply between latanoprost and bimatoprost, but the risk was significantly higher for travoprost. CONCLUSIONS: Based on resupply rates from a national pharmacy claims database, patients supplied with ocular hypotensive eyedrops were most persistent with prostaglandin (bimatoprost, latanoprost and travoprost) and dorzolamide-timolol combination eyedrops. Among the prostaglandins, persistency was highest with, and similar between, bimatoprost and latanoprost. Persistency should be taken into account when selecting the most appropriate eyedrop to treat glaucoma and ocular hypertension.